<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02354274</url>
  </required_header>
  <id_info>
    <org_study_id>NARLAL 2</org_study_id>
    <nct_id>NCT02354274</nct_id>
  </id_info>
  <brief_title>Novel Approach to Radiotherapy in Locally Advanced Lung Cancer Concomitant Navelbine®</brief_title>
  <official_title>Novel Approach to Radiotherapy in Locally Advanced Lung Cancer - Heterogeneous FDG-guided Dose Escalation With Concomitant Navelbine®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Olfred Hansen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Naestved Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effect of escalation of radiation dose to tumor and lymph nodes based on&#xD;
      an inhomogeneous dose distribution controlled by FDG-PET positive areas compared to a&#xD;
      standard homogeneous dose spread&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the effect of escalation of radiation dose to tumor and lymph nodes based on&#xD;
      an inhomogeneous dose distribution controlled by FDG-PET-positive areas compared to a&#xD;
      standard homogeneous dose spread.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">October 2029</completion_date>
  <primary_completion_date type="Anticipated">October 2029</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Two independent radiation plans are made before randomization to ensure best available plans for both arms and trial.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Locoregional control (Tumor recurrency is assessed by scheduled CT (of the thorax and upper abdomen)</measure>
    <time_frame>5-7 years</time_frame>
    <description>Tumor recurrency is assessed by scheduled CT (of the thorax and upper abdomen ) every 3 months combined with PET/CT every 9 months or if occurrence is clinically suspected. Suspicion of tumor relapse local, regional or distant should be verified by biopsy. Date of detected recurrence is the date of the imaging modality suspecting relapse. The patient will be censured at death without local relapse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity (graded after CTCAE 4.0 assessed by physician)</measure>
    <time_frame>10 years</time_frame>
    <description>Acute and late toxicity graded after CTCAE 4.0 assessed by physician at scheduled follow-up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>15 years</time_frame>
    <description>Time from randomization to exact date of death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>15 years</time_frame>
    <description>Time from randomization to date of progression, death, or occurence of metastatic disease</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Standard: Homogeneous dose plan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment will be given over 33 treatments. The dose is 66 Gy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escalation: Inhomogeneous dose plan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation dose is increased to tumor and lymph nodes based on an inhomogeneous dose distribution determined by the most active ( FDG-PET criteria ) area of the node compared to a standard uniform dose distribution.&#xD;
Treatment will be given over 33 treatments. The dose is as high as possible taking the tolerance of the normal tissue into consideration</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Escalated: Inhomogeneous dose plan</intervention_name>
    <arm_group_label>Escalation: Inhomogeneous dose plan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard: Homogeneous dose plan</intervention_name>
    <arm_group_label>Standard: Homogeneous dose plan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically or cytologically proven locally advanced NSCLC stage IIB&#xD;
             to IIIB&#xD;
&#xD;
          -  Performance status 0-1&#xD;
&#xD;
          -  Able to comply with treatment and follow study and follow-up procedures&#xD;
&#xD;
          -  Women must have negative pregnancy test&#xD;
&#xD;
          -  Signed, informed consent&#xD;
&#xD;
          -  Plan for radiotherapy with conventional 66 Gy/ 33 F, which meets all dosing limits two&#xD;
             normal tissue must be available&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any unstable systemic disorder (including infection , unstable angina, congestive&#xD;
             heart failure , severe liver , kidney or metabolic disease)&#xD;
&#xD;
          -  Need for nasal oxygen&#xD;
&#xD;
          -  Former thoracic radiotherapy, unless there is no significant overlap with previous&#xD;
             fields&#xD;
&#xD;
          -  Any other active malignant disease&#xD;
&#xD;
          -  Unable to take oral medications or needing intravenous nutrition&#xD;
&#xD;
          -  Ulcer&#xD;
&#xD;
          -  Nursing women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olfred Hansen, MD</last_name>
    <phone>+4565411867</phone>
    <email>olfred.hansen@rsyd.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Svetlana Kunwald, MD</last_name>
    </contact>
    <investigator>
      <last_name>Svetlana Kunwald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne M. Knap, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marianne M. Knap, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gitte F. Persson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev University Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon L. Andersen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jon L. Andersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Naestved Hospital</name>
      <address>
        <city>Naestved</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Wederwang, MD</last_name>
      <email>kwd@regionsjaelland.dk</email>
    </contact>
    <investigator>
      <last_name>Kim Wedervang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olfred Hansen, MD</last_name>
      <phone>+45 6541 1867</phone>
      <email>olfred.hansen@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Olfred Hansen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tine Schytte, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christa Haugaard, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christa Haugaard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 19, 2015</study_first_submitted>
  <study_first_submitted_qc>February 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2015</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Olfred Hansen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

